Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02756637 · ClinicalTrials.gov registry record
Neutrophil-to-Lymphocyte Ratio in Bladder Cancer: A Secondary Biomarker Analysis of SWOG 8710
A clinical trial, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- 634
- Enrollment target
NCT02756637 is a clinical trial that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 634 participants.
The verdict
NCT02756637 has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- 634 participants
- Enrollment target
Study Summary
The purpose of this study is to perform a secondary analysis of SWOG 8710 to assess NLRs value as a biomarker. Specifically, the investigators test two hypotheses: 1) that baseline NLR is correlated with overall survival after curative treatment for BC and 2) that baseline NLR is correlated with the survival benefit of NAC. The study will look at the data from participants of the SWOG 8710 study.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 634 participants |
| Start Date | 2016-04 |
| Est. Completion | 2016-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02756637
The ClinicalTrials.gov registry entry for NCT02756637 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 634 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02756637 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02756637 about?
NCT02756637 is a clinical study titled "Neutrophil-to-Lymphocyte Ratio in Bladder Cancer: A Secondary Biomarker Analysis of SWOG 8710". The purpose of this study is to perform a secondary analysis of SWOG 8710 to assess NLRs value as a biomarker. Specifically, the investigators test two hypotheses: 1) that baseline NLR is correlated with overall survival after curative treatment for BC and 2) that baseline NLR is correlated with the...
What is the current status of trial NCT02756637?
This trial is currently completed. The enrollment target is 634 participants. The study started on 2016-04. Estimated completion is 2016-11.
Who is sponsoring clinical trial NCT02756637?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.